Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions
COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has completed its acquisition of the travel vaccine portfolio from Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”).
With the closing of this transaction, Bavarian Nordic acquires two marketed vaccines – Vivotif® for the prevention of typhoid fever and Vaxchora® for the prevention of cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus. The acquisition also includes US-based research and development facilities and a Swiss-based biologics manufacturing facility, and EU/US-based commercial operations with a specialty salesforce.
“With the closing of this transaction, we have taken a significant step forward on our path towards becoming one of the largest pure play vaccine companies,” said Paul Chaplin, President, and Chief Executive Officer of Bavarian Nordic. “The acquisition will reinforce our leading position in travel vaccines and expand our presence across key markets, in addition to providing opportunities for further growth. With the addition of facilities across both the US and Europe, we are strengthening our R&D and manufacturing capabilities and are pleased to welcome nearly 300 new employees to join us in our efforts to develop and deliver more life-saving vaccines around the world.”
Upon closing, Bavarian Nordic has made a cash payment to Emergent of USD 274 million, which includes estimated adjustments for net working capital, debt and other customary closing adjustments. The actual value of the estimated adjustments will be assessed post-closing and could lead to minor changes. In addition, Emergent is eligible to receive additional future payments of up to USD 110 million conditioned upon the achievement of milestones related to the successful development of the Chikungunya vaccine (USD 80 million) and sales performance of the marketed vaccines (USD 30 million).
An updated and fully consolidated financial guidance is expected to be issued at the latest in connection with the announcement of the 2023 half-year financial report in August 2023.
Morgan Stanley acted as an advisor in this transaction, while Nordea and Cooley acted as financial and legal advisors respectively.
For more information about the transaction, see company announcement no. 03/2023.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. Using our live virus vaccine platform technology, MVA-BN® and in-licensed technologies, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system. For more information visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 19 / 2023
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nyxoah Strengthens its Executive Leadership Team28.11.2023 22:30:00 CET | Press release
Nyxoah Strengthens its Executive Leadership Team Francis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah’s Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector. Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market. “Nyxoah is entering the most exciting time in the Company’s history, with data fro
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update28.11.2023 22:15:00 CET | Press release
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European CommissionApprovability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024Management will conduct a business update conference call and live webcast on Thursday November 29, 2023, at 8:00 am ET (13:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2023 and pr
RÄTTELSE: Saknad MAR-etikett i tidigare pressmeddelande – ”Anoto ingår ett avtal för 1,1 miljoner USD avseende försäljning av pennor och treåriga mjukvarulicenser med Deutsche Telekom”28.11.2023 19:15:00 CET | Pressemelding
Anoto Group AB (publ) utfärdar en rättelse av pressmeddelandet som publicerades tidigare idag. Rättelsen avser att pressmeddelandet saknade MAR-etikett med hänvisning till EU:s marknadsmissbruksförordning (MAR). Följande information skulle ha varit med i pressmeddelandet: ”Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 28 november 2023, kl. 08:00 CEST.” Nedan publiceras det korrekta pressmeddelandet i sin helhet. Stockholm den 28 november 2023 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar idag att bolaget har tecknat ett upphandlingsavtal som avser försäljning av nya pennor, samt ett treårigt mjukvarulicensavtal med Deutsche Telekom AG (”Deutsche Telekom”). Deutsche Telekom är en av de äldsta kunderna inom Anotos affärssegment Forms och avtalet innebär att ramverket inom vilket Anoto och Deutsche T
CORRECTION: Missing MAR label in previous press release – “Anoto enters into a USD 1.1 million agreement for the sale of pens and three-year software licenses with Deutsche Telekom”28.11.2023 19:15:00 CET | Press release
Anoto Group AB (publ) issues a correction to the press release published earlier today. The correction refers to the fact that the press release lacked a MAR label with reference to the EU Market Abuse Regulation (MAR). The following information should have been included in the press release: ”This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication 28 November 2023, at 08:00 CEST.” The correct press release is published in its entirety below. Stockholm, 28 November 2023 – Anoto Group AB (publ) ("Anoto" or the "Company") today announces that it has signed a procurement agreement relating to the sale of new pens, plus a new three-year software licensing agreement with Deutsche Telekom AG (“Deutsche Telekom”). Deutsche Telekom is one of the oldest customers of Anoto’s Forms business and this agreement means that the framework withi
Status for Selskabets tilgodehavende hos Portinho S.A.28.11.2023 18:30:48 CET | pressemeddelelse
28. november 2023 Meddelelse nr. 46 Status for Selskabets tilgodehavende hos Portinho S.A. Selskabets bestyrelse, valgt ind i forbindelse med at Selskabet blev omdannet til en lægemiddelvirksomhed, og direktion har i længere tid, haft en meget tæt dialog med ledelsen i Portinho S.A. om indfrielse af Selskabets tilgodehavende hos Portinho S.A., der stammer fra tiden før Selskabet blev omdannet til en lægemiddelvirksomhed. Selskabets bestyrelse og direktion har sideløbende allokeret betydelige ressourcer til at afdække, hvilke dispositioner der fra den tidligere ledelse oprindeligt førte til etableringen af tilgodehavendet samt rationalet for de efterfølgende dispositioner af den tidligere ledelse, der har indvirket på tilgodehavendets vandring. Dette arbejde pågår forsat med blandt andet bistand fra både dansk og portugisisk juridisk rådgiver. Omfanget og vurderingen af de foreløbige resultater af undersøgelsesarbejdet har ført til, at det ikke længere er Selskabets vurdering, at tilgod